Lipid metabolism in hepatic steatosis

Clinics in Liver Disease

Volumn 8, Issue 3, 2004, Pages 639-671

  Bradbury, Michael W ^a   Berk, Paul D ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Cell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHYLOMICRON; INSULIN; LIPID; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

DIGESTION; FAT BODY; FAT INTAKE; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; FIBROSIS; GLUCOSE ABSORPTION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID ABSORPTION; LIPID ANALYSIS; LIPID METABOLISM; LIVER; LIVER CELL; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; FATTY ACIDS; FATTY LIVER; HUMANS; MALE; RATS; RATS, WISTAR; RATS, ZUCKER; TRIGLYCERIDES;

EID: 4344589923     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.04.005     Document Type: Review

References (183)

1. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 21:2001;3-16
2. Brunt E.M., Tiniakos D.G. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol. 16:2002;691-707
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 346:2002;1221-1231
4. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 16:2002;663-678
5. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 34:2002;255-262
6. Mulhall B.P., Ong J.P., Younossi Z.M. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 17:2002;1136-1143
7. Scheen A.J., Luyckx F.H. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 16:2002;703-716
8. Youssef W.I., McCullough A.J. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 16:2002;733-747
9. The Surgeon General's call to action to prevent and decrease overweight and obesity - 2001. US Department of Health and Human Services, Public Health Service Office of the Surgeon General; 2001. Washington, DC, Government Printing Office
10. Yanovski S.Z., Yanovski J.A. Obesity. N Engl J Med. 346:2002;591-602
11. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288:2002;1723-1737
12. Flegal K.M., Carroll M.D., Kuczmarski R.J., et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 22:1998;39-47
13. Kopelman P.G. Obesity as a medical problem. Nature. 404:2000;635-643
14. Wolf A.M., Colditz G.A. Current estimates of the economic cost of obesity in the United States. Obes Res. 6:1998;97-106
15. Kral J.G. Morbidity of severe obesity. Surg Clin North Am. 81:2001;1039-1061
16. National Institutes of Health and National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. ChIIC: Health risks of overweight and obesity. Obes Res. 6(Suppl 2):1998;71S-80S
17. Allison D.B., Fontaine K.R., Manson J.E., et al. Annual deaths attributable to obesity in the United States. JAMA. 282:1999;1530-1538
18. Oldridge N.B., Stump T.E., Nothwehr F.K., et al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol. 54:2001;928-934
19. Field A.E., Coakley E.H., Must A., et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 161:2001;1581-1586
20. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 21:1998;518-524
21. Clark C.M. Jr. How should we respond to the worldwide diabetes epidemic? Diabetes Care. 21:1998;475-476
22. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 21:1998;1414-1431
23. Ferris F.L. III, Davis M.D., Aiello L.M. Treatment of diabetic retinopathy. N Engl J Med. 341:1999;667-678
24. Olefsky J.M. Prospects for research in diabetes mellitus. JAMA. 285:2001;628-632
25. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 341:1999;1127-1133
26. Youssef W., McCullough A.J. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 13:2002;17-30
27. Roberts E.A. Steatohepatitis in children. Best Pract Res Clin Gastroenterol. 16:2002;749-765
28. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 98:2003;960-967
29. Ruhl C.E., Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 124:2003;71-79
30. Skelly M.M., James P.D., Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 35:2001;195-199
31. Hilden N., Christofferson P., Juhl E., et al. Liver histology in a normal population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol. 12:1977;593-597
32. Brolin R.E., Bradley L.J., Taliwal R.V. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg. 133:1998;84-88
33. Molloy R.M., Komorowski R., Varma R.R. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg. 3:1997;177-178
34. Zakim D. Metabolism of glucose and fatty acids by the liver. Boyer T.D., Zakim D. Hepatology. 4th edition:2003;49-80 WB Saunders, Philadelphia
35. Kamp F., Guo W., Souto R., et al. Rapid flip-flop of oleic acid across the plasma membrane of adipocytes. J Biol Chem. 278:2003;7988-7995
36. Pownall H.J., Hamilton J.A. Energy translocation across cell membranes and membrane models. Acta Physiol Scand. 178:2003;357-365
37. Abumrad N.A., Park J.H., Park C.R. Permeation of long-chain fatty acid into adipocytes. Kinetics, specificity, and evidence for involvement of a membrane protein. J Biol Chem. 259:1984;8945-8953
38. Abumrad N.A., Perkins R.C., Park J.H., et al. Mechanism of long chain fatty acid permeation in the isolated adipocyte. J Biol Chem. 256:1981;9183-9191
39. Bonen A., Luiken J.J., Liu S., et al. Palmitate transport and fatty acid transporters in red and white muscles. Am J Physiol. 275:1998;E471-E478
40. Fan X., Bradbury M.W., Berk P.D. Leptin and insulin modulate nutrient partitioning and weight loss in ob/ob mice through regulation of long-chain fatty acid uptake by adipocytes. J Nutr. 133:2003;2707-2715
41. Luiken J.J., Schaap F.G., Van Nieuwenhoven F.A., et al. Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids. 34:1999;S169-S175
42. Luiken J.J., Turcotte L.P., Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J Lipid Res. 40:1999;1007-1016
43. Schwieterman W., Sorrentino D., Potter B.J., et al. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut. Proc Natl Acad Sci U S A. 85:1988;359-363
44. Stremmel W., Berk P.D. Hepatocellular influx of [14C]oleate reflects membrane transport rather than intracellular metabolism or binding. Proc Natl Acad Sci U S A. 83:1986;3086-3090
45. Stremmel W., Strohmeyer G., Berk P.D. Hepatocellular uptake of oleate is energy dependent, sodium linked, and inhibited by an antibody to a hepatocyte plasma membrane fatty acid binding protein. Proc Natl Acad Sci U S A. 83:1986;3584-3588
46. Stump D.D., Nunes R.M., Sorrentino D., et al. Characteristics of oleate binding to liver plasma membranes and its uptake by isolated hepatocytes. J Hepatol. 16:1992;304-315
47. Trimble M.E. Mediated transport of long-chain fatty acids by rat renal basolateral membranes. Am J Physiol. 257:1989;F539-F546
48. Abumrad N., Harmon C., Ibrahimi A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. J Lipid Res. 39:1998;2309-2318
49. Abumrad N.A., Sfeir Z., Connelly M.A., et al. Lipid transporters: membrane transport systems for cholesterol and fatty acids. Curr Opin Clin Nutr Metab Care. 3:2000;255-262
50. Berk P.D., Stump D.D. Mechanisms of cellular uptake of long chain free fatty acids. Mol Cell Biochem. 192:1999;17-31
51. Glatz J.F., Storch J. Unraveling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol. 12:2001;267-274
52. Stump D.D., Fan X., Berk P.D. Oleic acid uptake and binding by rat adipocytes define dual pathways for cellular fatty acid uptake. J Lipid Res. 42:2001;509-520
53. Zhou S.L., Gordon R.E., Bradbury M., et al. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells. Hepatology. 27:1998;1064-1074
54. Zhou S.L., Stump D., Kiang C.L., et al. Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake. Proc Soc Exp Biol Med. 208:1995;263-270
55. Zhou S.L., Stump D., Sorrentino D., et al. Adipocyte differentiation of 3T3-L1 cells involves augmented expression of a 43-kDa plasma membrane fatty acid-binding protein. J Biol Chem. 267:1992;14456-14461
56. Isola L.M., Zhou S.L., Kiang C.L., et al. 3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake. Proc Natl Acad Sci U S A. 92:1995;9866-9870
57. Sorrentino D., Robinson R.B., Kiang C.L., et al. At physiologic albumin/oleate concentrations oleate uptake by isolated hepatocytes, cardiac myocytes, and adipocytes is a saturable function of the unbound oleate concentration. Uptake kinetics are consistent with the conventional theory. J Clin Invest. 84:1989;1325-1333
58. Sorrentino D., Stump D., Potter B.J., et al. Oleate uptake by cardiac myocytes is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut. J Clin Invest. 82:1988;928-935
59. Stremmel W. Fatty acid uptake by isolated rat heart myocytes represents a carrier-mediated transport process. J Clin Invest. 81:1988;844-852
60. Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J Clin Invest. 82:1988;2001-2010
61. Sorrentino D., Berk P.D. Free fatty acids, albumin and the sinusoidal plasma membrane: concepts, trends and controversies. Tavoloni N., Berk P.D. Hepatic transport and bile secretion. 1993;197-210 Raven Press, New York
62. Sorrentino D., Stump D.D., Van Ness K., et al. Oleate uptake by isolated hepatocytes and the perfused rat liver is competitively inhibited by palmitate. Am J Physiol. 270:1996;G385-G392
63. Sorrentino D., Stump D.D., Zhou S.L., et al. The hepatocellular uptake of free fatty acids is selectively preserved during starvation. Gastroenterology. 107:1994;1415-1424
64. Sorrentino D., Zhou S.L., Kokkotou E., et al. Sex differences in hepatic fatty acid uptake reflect a greater affinity of the transport system in females. Am J Physiol. 263:1992;G380-G385
65. Stremmel W., Strohmeyer G., Borchard F., et al. Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc Natl Acad Sci U S A. 82:1985;4-8
66. Berk P.D., Wada H., Horio Y., et al. Plasma membrane fatty acid-binding protein and mitochondrial glutamic-oxaloacetic transaminase of rat liver are related. Proc Natl Acad Sci U S A. 87:1990;3484-3488
67. Stump D.D., Zhou S.L., Berk P.D. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver. Am J Physiol. 265:1993;G894-G902
68. Kamp F., Hamilton J.A., Kamp F., et al. Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers. Biochemistry. 32:1993;11074-11086
69. Stremmel W., Diede H.E., Rodilla-Sala E., et al. The membrane fatty acid-binding protein is not identical to mitochondrial glutamic oxaloacetic transaminase (mGOT). Mol Cell Biochem. 98:1990;191-199
70. Zhou S.L., Stump D., Isola L., et al. Constitutive expression of a saturable transport system for nonesterified fatty acids in Xenopus laevis oocytes. Biochem J. 297:1994;315-319
71. Stremmel W., Theilmann L. Selective inhibition of long-chain fatty acid uptake in short-term cultured rat hepatocytes by an antibody to the rat liver plasma membrane fatty acid-binding protein. Biochimica et Biophysica acta Biophys Acta. 877:1986;191-197
72. Potter B.J., Berk P.D. The liver plasma membrane fatty acid binding protein. Tavoloni N., Berk P.D. Hepatic transport and bile secretion. 1993;253-267 Raven Press, New York
73. Zhou S.L., Gordon R., Kiang C.L., Stump D.D., Bradbury M., Isola L.M., et al. Intracellular movement and cellular export of mitochondrial aspartate aminotransferase from hepatoma cell lines. abstract Hepatology. 24:1996;128A
74. Bradbury M.W., Delavega L., Stockert R.J., Berk P.D. Green fluorescent protein-tagged mitochondrial aspartate aminotransferase illustrates the intracellular sorting of the native enzyme. abstract Hepatology. 28:1998;511A
75. Bradbury M., Fan X.Q., Stump D.D., Odin J.A., Guarnieri F., Berk P.D., et al. Mapping the fatty acid binding site in hepatic plasma membrane fatty acid binding protein with molecular modeling and mutagenesis. abstract Hepatology. 34:2001;256A
76. Bradbury M.W., Berk P.D. Cellular uptake of long chain free fatty acids: the structure and function of plasma membrane fatty acid binding protein. Adv Mol Cell Biol. 33:2004;47-81
77. Abumrad N.A., el Maghrabi M.R., Amri E.Z., et al. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 268:1993;17665-17668
78. Harmon C.M., Luce P., Beth A.H., et al. Labeling of adipocyte membranes by sulfo-N-succinimidyl derivatives of long-chain fatty acids: inhibition of fatty acid transport. J Membr Biol. 121:1991;261-268
79. Schaffer J.E., Lodish H.F. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell. 79:1994;427-436
80. Stahl A., Gimeno R.E., Tartaglia L.A., et al. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 12:2001;266-273
81. Hui T.Y., Bernlohr D.A. Fatty acid transporters in animal cells. Front Biosci. 2:1997;d222-d231
82. Kolleck I., Guthmann F., Ladhoff A.M., et al. Cellular cholesterol stimulates acute uptake of palmitate by redistribution of fatty acid translocase in type II pneumocytes. Biochemistry. 41:2002;6369-6375
83. Stremmel W., Pohl L., Ring A., et al. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids. 36:2001;981-989
84. Trigatti B.L., Anderson R.G., Gerber G.E. Identification of caveolin-1 as a fatty acid binding protein. Biochem Biophys Res Commun. 255:1999;34-39
85. Trigatti B.L., Mangroo D., Gerber G.E. Photoaffinity labeling and fatty acid permeation in 3T3-L1 adipocytes. J Biol Chem. 266:1991;22621-22625
86. Febbraio M., Hajjar D.P., Silverstein R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 108:2001;785-791
87. Baillie A.G., Coburn C.T., Abumrad N.A. Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. J Membr Biol. 153:1996;75-81
88. Berk P.D., Zhou S., Kiang C., et al. Selective up-regulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents. J Biol Chem. 274:1999;28626-28631
89. Greenwalt D.E., Scheck S.H., Rhinehart-Jones T. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest. 96:1995;1382-1388
90. Ibrahimi A., Sfeir Z., Magharaie H., et al. Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci U S A. 93:1996;2646-2651
91. Poirier H., Degrace P., Niot I., et al. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP). Eur J Biochem. 238:1996;368-373
92. Sfeir Z., Ibrahimi A., Amri E., et al. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot Essent Fatty Acids. 57:1997;17-21
93. Tanaka T., Sohmiya K., Kawamura K. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J Mol Cell Cardiol. 29:1997;121-127
94. Binnert C., Koistinen H.A., Martin G., et al. Fatty acid transport protein-1 mRNA expression in skeletal muscle and in adipose tissue in humans. Am J Physiol Endocrinol Metab. 279:2000;E1072-E1079
95. Luiken J.J., Arumugam Y., Dyck D.J., et al. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem. 276:2001;40567-40573
96. Hajri T., Ibrahimi A., Coburn C.T., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem. 276:2001;23661-23666
97. Luiken J.J., Willems J., van der Vusse G.J., et al. Electrostimulation enhances FAT/CD36-mediated long-chain fatty acid uptake by isolated rat cardiac myocytes. Am J Physiol Endocrinol Metab. 281:2001;E704-E712
98. Nozaki S., Tanaka T., Yamashita S., et al. CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem. 192:1999;129-135
99. Hirsch D., Stahl A., Lodish H.F. A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A. 95:1998;8625-8629
100. Coe N.R., Smith A.J., Frohnert B.I., et al. The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem. 274:1999;36300-36304
101. Faergeman N.J., DiRusso C.C., Elberger A., et al. Disruption of the Saccharomyces cerevisiae homologue to the murine fatty acid transport protein impairs uptake and growth on long chain fatty acids. J Biol Chem. 272:1997;8531-8538
102. Stuhlsatz-Krouper S.M., Bennett N.E., Schaffer J.E. Substitution of alanine for serine 250 in the murine fatty acid transport protein inhibits long chain fatty acid transport. J Biol Chem. 273:1998;28642-28650
103. Watkins P.A., Lu J.F., Steinberg S.J., et al. Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations. J Biol Chem. 273:1998;18210-18219
104. Martin G., Schoonjans K., Staels B., et al. PPAR gamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis. 137:1998;S75-S80
105. Prieto R.M., Stremmel W., Sales C., et al. Oleic acid uptake by jejunal and ileal rat brush border membrane vesicles. Eur J Med Res. 1:1996;199-203
106. Stahl A., Hirsch D.J., Gimeno R.E., et al. Identification of the major intestinal fatty acid transport protein. Mol Cell. 4:1999;299-308
107. Berk P.D., Zhou S.L., Kiang C.L., et al. Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus. J Biol Chem. 272:1997;8830-8835
108. Memon R.A., Feingold K.R., Moser A.H., et al. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am J Physiol. 274:1998;E210-E217
109. Motojima K., Passilly P., Peters J.M., et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem. 273:1998;16710-16714
110. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:1996;907-925
111. Turcotte L.P., Swenberger J.R., Tucker M.Z., et al. Training-induced elevation in FABP(PM) is associated with increased palmitate use in contracting muscle. J Appl Physiol. 87:1999;285-293
112. Hui T.Y., Frohnert B.I., Smith A.J., et al. Characterization of the murine fatty acid transport protein gene and its insulin response sequence. J Biol Chem. 273:1998;27420-27429
113. Man M.Z., Hui T.Y., Schaffer J.E., et al. Regulation of the murine adipocyte fatty acid transporter gene by insulin. Mol Endocrinol. 10:1996;1021-1028
114. Stremmel W., Lotz G., Strohmeyer G., et al. Identification, isolation, and partial characterization of a fatty acid binding protein from rat jejunal microvillous membranes. J Clin Invest. 75:1985;1068-1076
115. Tennyson G.E., Sabatos C.A., Higuchi K., et al. Expression of apolipoprotein B mRNAs encoding higher- and lower-molecular weight isoproteins in rat liver and intestine. Proc Natl Acad Sci U S A. 86:1989;500-504
116. Merkel M., Eckel R.H., Goldberg I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 43:2002;1997-2006
117. Preiss-Landl K., Zimmermann R., Hammerle G., et al. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol. 13:2002;471-481
118. Miller J.P. Liver disease, alcohol, and lipoprotein metabolism. Zakim D., Boyer T.D. Hepatology. 4th edition:2003;127-148 Saunders, Philadelphia
119. Wetterau J.R., Lin M.C., Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1345:1997;136-150
120. Leibel R.L., Chung W.K., Chua S.C. Jr. The molecular genetics of rodent single gene obesities. J Biol Chem. 272:1997;31937-31940
121. Lieber C.S., DeCarli L.M. Animal models of chronic ethanol toxicity. Methods Enzymol. 233:1994;585-594
122. Bjorntorp P., Bergman H., Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand. 185:1969;351-356
123. Koteish A., Diehl A.M. Animal models of steatosis. Semin Liver Dis. 21:2001;89-104
124. Saleh J., Sniderman A.D., Cianflone K. Regulation of plasma fatty acid metabolism. Clin Chim Acta. 286:1999;163-180
125. Bjorntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol. 5:1994;166-174
126. Groop L.C., Saloranta C., Shank M., et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 72:1991;96-107
127. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 258:1992;766-770
128. McGarry J.D. Disordered metabolism in diabetes: have we underemphasized the fat component? J Cell Biochem. 55:1994;29-38
129. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 44:1995;863-870
130. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 14:2003;281-287
131. Unger R.H. The physiology of cellular liporegulation. Annu Rev Physiol. 65:2003;333-347
132. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 14:1998;263-283
133. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:1963;785-789
134. Randle P.J., Kerbey A.L., Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev. 4:1988;623-638
135. Cohen P., Ntambi J.M., Friedman J.M. Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord. 3:2003;271-280
136. Ntambi J.M., Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res. 43:2004;91-104
137. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res. 40:1999;1549-1558
138. Cohen P., Miyazaki M., Socci N.D., et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 297:2002;240-243
139. Ntambi J.M., Miyazaki M., Stoehr J.P., et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A. 99:2002;11482-11486
140. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes. 111:2003;246-250
141. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol. 8:1997;146-153
142. Charlton M., Sreekumar R., Rasmussen D., et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35:2002;898-904
143. Adeli K., Taghibiglou C., Van Iderstine S.C., et al. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 11:2001;170-176
144. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 67:1995;101-154
145. Letteron P., Sutton A., Mansouri A., et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 38:2003;133-140
146. Raabe M., Veniant M.M., Sullivan M.A., et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 103:1999;1287-1298
147. Bjorkegren J., Beigneux A., Bergo M.O., et al. Blocking the secretion of hepatic very low-density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem. 277:2002;5476-5483
148. Partin J.S., Partin J.C., Schubert W.K., et al. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology. 67:1974;107-118
149. Karpe F., Lundahl B., Ehrenborg E., et al. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol. 18:1998;756-761
150. Bernard S., Touzet S., Personne I., et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia. 43:2000;995-999
151. Pessayre D., Berson A., Fromenty B., et al. Mitochondria in steatohepatitis. Semin Liver Dis. 21:2001;57-69
152. Lodish H.F., Berk A., Zipursky S.L., et al. Molecular cell biology. 4th edition:1999;618-648 W.H. Freeman, New York
153. Chalasani N., Gorski J.C., Asghar M.S., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 37:2003;544-550
154. Robertson G., Leclercq I., Farrell G.C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 281:2001;G1135-G1139
155. Reddy J.K. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 281:2001;G1333-G1339
156. Bernlohr D.A., Coe N.R., Simpson M.A., et al. Regulation of gene expression in adipose cells by polyunsaturated fatty acids. Adv Exp Med Biol. 422:1997;145-156
157. Distel R.J., Robinson G.S., Spiegelman B.M. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J Biol Chem. 267:1992;5937-5941
158. Sessler A.M., Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. J Nutr. 128:1998;923-926
159. Haque M., Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 16:2002;709-731
160. Remesar X., Rafecas I., Fernandez-Lopez J.A., et al. Is leptin an insulin counter-regulatory hormone? FEBS Lett. 402:1997;9-11
161. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:2002;1125-1131
162. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 40:2001;439-452
163. Ferrante A.W. Jr., Thearle M., Liao T., et al. Effects of leptin deficiency and short-term repletion on hepatic gene expression in genetically obese mice. Diabetes. 50:2001;2268-2278
164. Liang C.P., Tall A.R. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem. 276:2001;49066-49076
165. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1302:1996;93-109
166. Soukas A., Cohen P., Socci N.D., et al. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 14:2000;963-980
167. Segal K.R., Landt M., Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes. 45:1996;988-991
168. Day C.P., James O.F. Steatohepatitis: a tale of two hits? Gastroenterology. 114:1998;842-845
169. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 125:2003;437-443
170. Koteish A., Mae D.A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol. 16:2002;679-690
171. Caldwell S.H., Swerdlow R.H., Khan E.M., et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol. 31:1999;430-434
172. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:2001;1183-1192
173. Perez-Carreras M., Del Hoyo P., Martin M.A., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 38:2003;999-1007
174. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis. 5:2001;315-334
175. Albanis E., Friedman S.L. Noninvasive markers of hepatic fibrosis. Clin Perspect Gastroenterol. 5:2002;182-188
176. Albanis E., Safadi R., Friedman S.L. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep. 5:2003;48-56
177. Cortez-Pinto H., Baptista A., Camilo M.E., et al. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterology. 48:2001;87-90
178. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275:2000;2247-2250
179. Friedman S.L. Liver fibrosis - from bench to bedside. J Hepatol. 38(Suppl 1):2003;S38-S53
180. Hui A., Friedman S.L. Molecular basis of hepatic fibrosis. Expert Revs Molec Med. Feb 14:2003;1-23
181. Washington K., Wright K., Shyr Y., et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol. 31:2000;822-828
182. Petrescu O., Fan X.O., Bradbury M.W., Berk P.D. Selective regulation of long chain fatty acid uptake across adipocyte plasma membranes is a control point for body adiposity. abstract Gastroenterology. 124:2003;A70
183. Fan X., Gentileschi P., Gagner M., Berk P.D. Long chain free fatty acid uptake is upregulated in omental adipocytes from obese human subjects. abstract Obesity Research. 9:2001;141S